Navigation Links
Bioniche Pharma and Synerx Launch Isosulfan Blue Injection 1%
Date:7/28/2010

LAKE FOREST, Ill., July 28 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC announced today the FDA approval and launch of Isosulfan Blue Injection 1%.

(Photo:  http://photos.prnewswire.com/prnh/20100728/CG42156)

(Photo:  http://www.newscom.com/cgi-bin/prnh/20100728/CG42156)

(Logo:  http://photos.prnewswire.com/prnh/20080702/AQW070LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)

"Launching the first and only generic for Isosulfan Blue Injection 1% in the US reaffirms our commitment to introducing generic niche products, which allows hospitals and pharmacies an option in the buying process," said George Zorich, President, US Operations for Bioniche Pharma.

Isosulfan Blue Injection 1% will be supplied in a carton containing six 5mL (10 mg/mL)

single use vials.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, including anaesthesiology, orthopedics, rheumatology, urology, and dermatology. An internal development pipeline and an aggressive acquisition strategy for products fuel the company's growth. RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois, acquired Bioniche Pharma in February 2006. More information about Bioniche Pharma and prescribing information for its products can be found at www.bionichepharma.com.

About Synerx Pharma:

Synerx Pharma, LLC is a privately held corporation located in historic Bucks County Pennsylvania. Established in January 2004, the company develops and brings to market select pharmaceutical products aimed at addressing unmet market needs, particularly those involving some combination of barriers to entry. The company focuses on developing cost effective specialty generic pharmaceuticals and small brand products. Synerx presently has eight FDA approved products, of which five were First Time Generic Approvals, and a development portfolio of ten projects at various stages of development in multiple dosage forms. More information can be found at www.synerxpharma.com.

Lymphazurin™ is a trademark of Tyco Healthcare Group LP


'/>"/>
SOURCE Bioniche Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business
2. RoundTable Healthcare Partners Announces Sale of Bioniche Pharma Holdings Limited to Mylan Inc.
3. Bioniche Pharma Acquires Seven New Products From GeneraMedix Inc.
4. Bioniche Pharma Launches Ibutilide Fumarate Injection
5. Bioniche Pharma and Academic Pharmaceuticals, Inc. Announce the Introduction of Sotalol Hydrochloride Injection
6. Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
8. Topaz Pharmaceuticals Announces Positive Data from Topical Ivermectin Trials Presented at Society of Pediatric Dermatology
9. Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)
10. HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
11. Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017 EMD Serono, the biopharmaceutical business ... the U.S. and Canada , today announced ... poster presentation session at the 65 th Annual Pacific ... California on March 24 th .   ... real-world database collected from July 2009 to December 2015 containing ...
(Date:3/22/2017)... , March 22, 2017  Levine Cancer ... tomography (CT) unit designed to address lung cancer ... across the Carolinas. The mobile lung unit is ... cancer education and treatment interventions through integrated mobile ... Financial barriers and a lack of ...
(Date:3/22/2017)... SANTA CLARA, Calif. , March 22, 2017 ... diagnostic cardiology  solutions segment, Frost & Sullivan recognizes ... Sullivan Company of the Year Award. GE Healthcare,s ... offer end-to-end cardiac solutions has allowed it to ... competitive cardiac monitoring products space. In addition to ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... 22, 2017 , ... The Burke Medical Research Institute (BMRI) ... in basic neuroscience at the BMRI labs into new and improved treatments for ... vision, and cognition impaired by stroke, traumatic brain injury, cerebral palsy, and birth ...
(Date:3/22/2017)... VA (PRWEB) , ... March 22, 2017 , ... ... asset protection assistance and financial consultations to families and business owners in the ... support for the local American Cancer Society Relay For Life event. , Each ...
(Date:3/22/2017)... ... ... Schneider Insurance and Financial, a southern Montana firm providing asset protection and financial ... a charity event aimed at raising local support for Zoo Montana. , Zoo Montana ... home to a broad variety of animals from all over the world. Many of ...
(Date:3/22/2017)... ... March 22, 2017 , ... College basketball surges to its peak ... for recruiting – that is, recruiting people to be foster parents. Through a televised ... who are in foster care due to abuse, neglect and other family challenges. People ...
(Date:3/22/2017)... ... March 22, 2017 , ... NYC Chiropractor Dr. Steven ... was the first of its kind in the U.S. and focused on a new ... Amino BioFrequency Therapy to New York, and furthermore the first seminar in ...
Breaking Medicine News(10 mins):